[Lipid treatment in the period COVID-19]. / Tratamiento hipolipemiante en la era COVID-19.
Semergen
; 46(7): 497-502, 2020 Oct.
Article
in Spanish
| MEDLINE | ID: covidwho-688825
ABSTRACT
BACKGROUND AND OBJECTIVES:
The COVID-19 pandemic has shown that cardiovascular diseases carry a higher risk of mortality. Doubts have been raised regarding lipid therapy in these patients. The objectives are to analyze the efficacy and safety of lipid lowering therapy in patients with COVID-19. MATERIAL ANDMETHODS:
A review of the scientific literature was conducted in PubMed, CDC Reports, NIH, and NCBI SARS-CoV-2 using the keywords COVID-2, statins, ezetimibe, PCSK9 inhibitors, hypercholesterolemia, and hypolipidemic drugs.RESULTS:
The statins should continue to use patients with COVID-19 based on their efficacy, safety, immunosuppressive effects, anti-inflammatory availability and accessibility. Depending on the cardiovascular risk levels of these patients, the use of high potency statins and/or ezetimibe and/or iPCSK9 may be necessary in patients with high and very high cardiovascular risk. Patients treated with iPCSK9 should continue treatment for its beneficial effects in preventing cardiovascular disease. Patients with familial hypercholesterolemia and COVID-19 are especially vulnerable to cardiovascular disease and should continue to receive severe lipid lowering therapy.CONCLUSIONS:
In patients with COVID-19, the majority of baseline CVDs are of atherosclerotic origin, with the worst prediction for patients with high risk and very high risk of CVD. In these patients, intensive treatment with statins and/or fixed combination with ezetimibe and/or iPCSK9 plays a fundamental role.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Hypercholesterolemia
/
Hypolipidemic Agents
Type of study:
Prognostic study
/
Reviews
Topics:
Long Covid
Limits:
Humans
Language:
Spanish
Journal:
Semergen
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS